Published

Dimethyltryptamine (DMT): prevalence, user characteristics and abuse liability in a large global sample.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Journal of psychopharmacology (Oxford, England)
Date: 2014-01-01
Source: PubMed
DOI: 10.1177/0269881113513852
PubMed: 24284475

Authors

Winstock AR Kaar S Borschmann R

Watch author

Derived topics and classifications

psilocybin Observational Study Abuse Liability Observational Study

Citation graph

0 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.

Open citation network

Indexed papers citing this DOI

Dimethyltryptamine (DMT): prevalence, user characteristics and abuse liability in a large global sample.2014-01-01

Related papers

Direct Comparison of Altered States of Consciousness Induced by LSD, Psilocybin, and DMT in a Randomized, Placebo-controlled, Cross-over Trial in Healthy Participants (LPD-Study)ClinicalTrials.gov · 2025-03-27 Retrospective Observational Study of Intensity Effects in Psychedelic-assisted TreatmentClinicalTrials.gov · 2025-10-02 Comparative Acute Effects of LSD, Psilocybin and Mescaline in a Random-Order Placebo-Controlled Cross-Over Study in Healthy SubjectsClinicalTrials.gov · 2024-01-24 [Psychedelics and treatment of mental disorders: A survey of attitudes and knowledge among psychiatrists, general practitioners and psychologists in Iceland].Laeknabladid · 2023-11-01 Direct Comparison of Altered States of Consciousness Induced by LSD and Psilocybin in a Random-order Placebo-controlled Cross-over Study in Healthy SubjectsClinicalTrials.gov · 2021-04-27 The Role of Personal Experience for the Therapeutic Attitude in the Context of Substance-assisted Therapy TrainingClinicalTrials.gov · 2025-04-14 LSD Treatment in Persons Suffering From Anxiety Symptoms in Severe Somatic Diseases or in Psychiatric Anxiety Disorders: a Randomized, Double-blind, Placebo-controlled Phase II StudyClinicalTrials.gov · 2021-12-22